Financial Snapshot

Revenue
$4.544M
TTM
Gross Margin
-65.05%
TTM
Net Earnings
-$27.58M
TTM
Current Assets
Q3 2022
Current Liabilities
Q3 2022
Current Ratio
478.79%
Q3 2022
Total Assets
Q3 2022
Total Liabilities
Q3 2022
Book Value
$26.20M
Q3 2022
Cash
Q3 2022
P/E
-0.0002113
Sep 15, 2023 EST
Free Cash Flow
-$13.36M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $5.828 Thousand

About PLx Pharma Winddown Corp.

PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. The company is headquartered in Sparta, New Jersey and currently employs 16 full-time employees. The company went IPO on 2014-03-13. The firm is no longer into any business operations and it has filed voluntary petitions under Chapter 11 of the United States Bankruptcy Code.

Industry: Pharmaceutical Preparations Peers: Ampio Pharmaceuticals, Inc. TREX WIND-DOWN, INC. cbdMD, Inc. Eloxx Pharmaceuticals, Inc. Evofem Biosciences, Inc. JOHNSON & JOHNSON VYNE Therapeutics Inc. Unrivaled Brands, Inc. TITAN PHARMACEUTICALS INC Virpax Pharmaceuticals, Inc.